Related Experiment Video
Updated: Jul 16, 2026
02:47
Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
Published on: May 12, 2023
Developing strategies to link basic cardiovascular sciences with clinical drug development: another opportunity for
A M Feldman1, W J Koch, T L Force
1Department of Medicine, Jefferson Medical College, Philadelphia, Pennsylvania, USA. arthur.feldman@jefferson.edu
Clinical Pharmacology and Therapeutics
|March 30, 2007
Summary
Translational medicine advances drug discovery by bridging lab research and clinical application. Animal models offer crucial insights into potential drug cardiotoxicity, aiding safer clinical trial design.
Area of Science:
- Cardiovascular Research
- Translational Medicine
- Drug Development
Background:
- Translational medicine connects basic research to clinical applications, accelerating therapeutic initiatives.
- Its application in cardiovascular drug development and toxicity prediction for non-cardiac agents remains underutilized.
- Animal models are vital for understanding drug cardiotoxicity and designing clinical trials.
Purpose of the Study:
- To highlight the underuse of translational medicine in cardiovascular drug development.
- To emphasize the role of animal studies in predicting and mitigating drug-induced cardiotoxicity.
- To illustrate how preclinical data can inform drug development programs.
Main Methods:
- Review of existing literature on translational medicine and drug development.
- Analysis of case studies involving drug-induced cardiotoxicity.
- Discussion of the utility of animal models in preclinical safety assessments.
Main Results:
- Trastuzumab, cyclooxygenase inhibitors, and adenosine-receptor modulators exemplify drug programs where preclinical data could have informed development.
- Animal models provide essential data for identifying potential cardiovascular risks of new agents.
- Preclinical findings can guide the rational design of human clinical trials.
Conclusions:
- Translational medicine principles are crucial for advancing cardiovascular drug safety and efficacy.
- Animal models are indispensable tools for predicting cardiotoxicity and optimizing drug development pathways.
- Integrating preclinical insights enhances the safety and efficiency of evaluating new pharmacologic agents.
Related Concept Videos
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...